Last reviewed · How we verify
Dosing of enoxaparin for VTE prophylaxis
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Venous thromboembolism prophylaxis in surgical patients, Venous thromboembolism prophylaxis in medically ill patients, Treatment of acute deep vein thrombosis.
At a glance
| Generic name | Dosing of enoxaparin for VTE prophylaxis |
|---|---|
| Sponsor | Intermountain Health Care, Inc. |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Factor Xa and Factor IIa (via antithrombin III enhancement) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. It is used for venous thromboembolism (VTE) prophylaxis to prevent deep vein thrombosis and pulmonary embolism in at-risk patients.
Approved indications
- Venous thromboembolism prophylaxis in surgical patients
- Venous thromboembolism prophylaxis in medically ill patients
- Treatment of acute deep vein thrombosis
- Treatment of acute pulmonary embolism
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated liver enzymes
Key clinical trials
- Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention (PHASE3)
- Evaluation of Chemical Venous Thromboembolism Prophylaxis in Trauma
- Weight Based Enoxaparin in Trauma Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: